List view / Grid view
30 September 2013 | By Amgen
"These results further support the primary analysis reported at ASCO which demonstrated a statistically significant durable response rate..."
28 September 2013 | By Amgen
Trial evaluated nearly 1,000 patients with metastatic colorectal cancer...
25 September 2013 | By Amgen
Amgen And ShanghaiTech University agree plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University...
18 September 2013 | By Amgen
Amgen and Onyx Pharmaceuticals have announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Amgen's proposed acquisition of Onyx, was terminated early on Sept. 18, 2013...
11 September 2013 | By Amgen
Study links RAS mutations to Vectibix clinical response in patients with metastatic colorectal cancer...
3 September 2013 | By Amgen
First trial to evaluate cardiac myosin activator in patients with acute heart failure presented at ESC Congress 2013...
1 September 2013 | By Amgen
Results of analyses presented at ESC Congress 2013...
27 August 2013 | By Amgen
Amgen will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics...
25 August 2013 | By Amgen
Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash...
12 August 2013 | By Amgen
Amgen and Servier announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement...
16 July 2013 | By Amgen
Phase 2 study reports safety and efficacy results in patients with giant cell tumor of bone...
9 July 2013 | By Amgen
Amgen obtains US rights to novel EU-approved cardiovascular therapy; Servier receives option for omecamtiv mecarbil in Europe...
13 June 2013 | By Amgen
XGEVA becomes first FDA-approved treatment for this rare disease...
12 June 2013 | By Amgen
Study meets primary endpoint of progression-free survival...
12 June 2013 | By Amgen
Amgen and Cytokinetics announced an expansion of their strategic collaboration...
